NASDAQ
38.23USD
-2.05 (-5.09%)
We have scored 12 news catalysts on Harmony Biosciences Holdings, Inc. (HRMY) over the past 12 months. The biggest single-day move next to one of them came Aug 4, 2026, when HRMY closed +8.9%: “Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates”. Coverage across the window leans positive (average ticker sentiment +0.45). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
2.2B
P/E
—
EPS
—
Beta
1.01
52W range
25.52-43.49
Day range
37.08–39.76
Open
38.73
Prev close
40.28
Volume
1.1M
Avg volume
872.4K
Dividend
0.00
IPO
2020-08-19
Analysts publish price targets on HRMY, and they disagree. Where the share price actually sits among them shows which of their arguments the market is buying — and which it is ignoring.
7 analyst price targets from $34 to $70
as of 2026-09-14
The market is within 6% of the median target — broadly agreeing with the analysts.
The reconstruction
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Harmony Biosciences Holdings, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for HRMY: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical firm dedicated to developing and marketing therapies for individuals in the United States who suffer from rare neurological conditions. Their flagship product, WAKIX, is a prescription medication designed to treat excessive daytime sleepiness in adult patients diagnosed with narcolepsy. The company, which was founded in 2017, was formerly known as Harmony Biosciences II, Inc. before adopting its current name in February 2020. Harmony Biosciences Holdings, Inc. operates out of Plymouth Meeting, Pennsylvania.
The price sits at the 57th percentile of the $34-$70 model spread, roughly matching the median target and fully paying for the current business, while explicitly rejecting the bull cases for new pipeline drugs and the bear case for deceleration.
What the disagreement turns on
Whether the market is correct to give the BP-205 pipeline asset almost no credit, and whether unit volume data can detect early adoption that contradicts the price's required revenue decline.
The price pays for
It declines to pay for
Written by a language model from the published models, the reported segments and a reverse-DCF — not a recommendation, and not a house view.
Claim by claim
Computed at $41.52 on 2026-09-14 — the quote has since moved -8%, so read this as a record of what was priced in then, not now.
